Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioMarin: A Rare Disease Specialist With An Eye On The Long-Term

This article was originally published in The Pink Sheet Daily

Executive Summary

BioMarin is in the midst of a pivotal year, with several near-term data catalysts, the most important of which will be Phase III data on GALNS for the rare disease MPS IV.

You may also be interested in...



BioMarin Takes One Step Closer To Profitability With Positive GALNS Data

The orphan drug company reported positive Phase III data on its candidate for patients with the rare disease MPS IV and expects to file GALNS for FDA approval in the first quarter.

BioMarin Takes One Step Closer To Profitability With Positive GALNS Data

The orphan drug company reported positive Phase III data on its candidate for patients with the rare disease MPS IV and expects to file GALNS for FDA approval in the first quarter.

BioMarin May Be On Cusp Of Profitability, With GALNS The Key Determining Factor

At the Canaccord Genuity Global Growth Conference, the rare disease-focused biotech reiterated its goal to reach profitability in the near future with five pipeline programs potentially augmenting a portfolio of four marketed products.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel